DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform. New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine. According to a news release, results —presented at the American Diabetes Association (ADA) 81st […]
dariohealth
DarioHealth touts research on digital therapeutics for diabetes patients
DarioHealth (NSDQ:DRIO) announced today that recently published research supports its digital therapeutic platform for type 2 diabetes. New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealth’s digital therapeutics for diabetes management, monitoring […]
DarioHealth acquires PsyInnovations for $30M
DarioHealth announced that it entered into an agreement to acquire digital health company PsyInnovations for up to $30 million. PsyInnovations develops the wayForward behavioral digital health platform with AI-enabled screening to triage and navigate members to specific interventions, digital cognitive behavioral therapy (CBT), self-directed care, expert coaching and access to in-person and telehealth provider visits, according […]
DarioHealth partners with MediOrbis on virtual diabetes care platform
DarioHealth (NSDQ:DRIO) announced that it launched a new virtual care initiative with MediOrbis to improve virtual care for diabetes. New York-based DarioHealth’s collaboration with MediOrbis is slated to offer eligible Medicare members with diabetes a convenient method for virtual care that includes MediOrbis’ telehealth offerings and DarioHealth’s AI-powered remote patient monitoring, according to a news […]
DarioHealth ticks up before market opens on Q4 results
DarioHealth (NSDQ:DRIO) shares ticked up in pre-market trading today on fourth-quarter revenues that equaled the consensus forecast. The New York–based digital therapeutics company posted losses of –$9 million for the three months ended Dec. 31, 2020, representing a more than doubled bottom-line slide from the same quarter last year on sales growth of 15.7%. The […]
Abbott, Medtronic go head-to-head at ADA conference
Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology. The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller […]
7 medtech advances to improve diabetes treatment
Medtech and pharmaceutical companies have made several important strides over the past year when it comes to improving diabetes treatment. Multiple treatments and technologies have cleared regulatory hurdles and are now hitting the market and making the process of living with diabetes that much more manageable. Several different styles of therapy and devices have come […]
DarioHealth beats forecast with Q3 results
DarioHealth (NSDQ:DRIO) posted lower-than-expected net losses during the third quarter and met the consensus revenues forecast. The Israeli company, which makes mobile phone-compatible blood glucose and blood pressure monitors, reported losses of -$2.8 million, or -6¢ per share, on sales of $1.9 million for the three months ended Sept. 30. DarioHealth pared its losses by -31.0% […]
Dance Biopharm, DarioHealth partner up on smart inhaler
Dance Biopharm said today that it has partnered with DarioHealth (NSDQ:DRIO) to integrate Dance’s smart inhaler into DarioHealth’s digital therapeutics program. Durham, N.C.-based Dance Biopharm’s smart inhaler includes vibrating mesh designed to create a soft mist that improves medication coverage in the lung. In clinical trials, the device delivered insulin in mist form with a faster […]
DarioHealth prices $7m public offering
DarioHealth today priced an underwritten public offering of 4.8 million shares of common stock at 60¢ per share with additional pre-funded warrants. Pre-funded warrants offer 7.2 million shares of common stock at 59¢ each for gross proceeds of roughly $7.2 million. The pre-funded warrants have an exercise price of 0.01¢ and are exercisable until full […]
